Lutris- Pharma Intellectual Property (IP) is protected by a comprehensive patents portfolio: six patent families, five of them owned by Lutris -Pharma and one licensed from Memorial Slone-Kettering Cancer Center. Patents are filed in US, Europe and other countries, have more that 15 years life time and are planned to be extended beyond.
USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS
| PCT publication number: | WO17154001 |
| Application date: | March, 2017 |
| Owner: | Lutris Pharma Ltd. |
| Inventor: | Dr. Noa Shelach |
| Abstract (PCT): | The invention discloses compositions comprising BRaf inhibitors and uses thereof for treating and/or preventing by topical or systemic administration cutaneous conditions caused by treatment with EGFR inhibitors and/or PI3K inhibitors. |
| Status: | Granted in US and other countries |
NOVEL BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS
| PCT publication number: | WO19026065 |
| Application date: | July, 2018 |
| Owner: | Lutris Pharma Ltd. |
| Inventor: | Dr. Noa Shelach |
| Abstract (PCT): | The present invention discloses novel BRaf inhibitors, compositions comprising these inhibitors and uses thereof for the treatment, amelioration and/or prevention of cutaneous reactions. |
| Status: | Granted in US , Europe and other countries |
TREATMENT OF RADIATION DERMATITIS WITH BRAF INHIBITORS
| PCT publication number: | WO20165755 A1 |
| Application date: | November, 2020 |
| Owner: | Lutris Pharma Ltd. |
| Inventor: | Dr. Noa Shelach |
| Abstract (PCT): | The present invention relates to methods of treatment of radiation dermatitis, by administration to a subject in need thereof a composition comprising a therapeutically and/or prophylactically effective amount of at least one BRaf inhibitor or a combination thereof and a pharmaceutically acceptable carrier or excipient. |
| Status: | Granted in US |
USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR DOWNSTREAM EFFECTORS - INDUCED CUTANEOUS REACTIONS
| PCT publication number: | WO22136912 |
| Application date: | November, 2021 |
| Owner: | Lutris Pharma Ltd. |
| Inventor: | Dr. Noa Shelach , Galit Zelinger |
| Abstract (PCT): | Pharmaceutical topical compositions comprising compound of Formula IV and method of using pharmaceutical topical compositions comprising compound of Formula IV for the treatment or prevention of EGFR inhibitor, Pl3K inhibitor, MEK inhibitor and/or HER dimerization inhibitor-induced acneiform lesions in a subject in need thereof are provided. |
| Status: | Published |
USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR
| PCT publication number: | WO19032717 |
| Application date: | August, 2018 |
| Owner: | Memorial Sloan-Kettering Cancer Center, Licensed by Lutris Pharma |
| Inventor: | Dr. Neal Rosen, Dr. Noa Shelach |
| Abstract (PCT): | Compositions comprising BRAF inhibitors and uses thereof for treating and/or preventing a MEK inhibitor-associated cutaneous condition in a subject. |
| Status: | Granted in US |
USE OF ISOQUINOLINE-1,5-DIAMINES FOR WOUND HEALING
| PCT publication number: | |
| Application date: | June , 2022 |
| Owner: | Lutris Pharma |
| Inventor: | Dr. Noa Shelach |
| Abstract (PCT): | |
| Status: | PCT filed |